Open an account

Kyntra Bio

KYNB · NASDAQ

$5.28+$0.00 (+0.00%)TodayMarket closed ·
Prev close $5.28

About KYNB

Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 34 full-time employees. The company went IPO on 2014-11-14. The firm is focused on development of novel therapies in oncology and rare disease. The firm continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.

Employees
34
Headquarters
San Francisco, California
Listed
Nov 14, 2014
Sector
Health Care
Industry
Biotechnology
Website
kyntrabio.com

KYNB key statistics

Market cap
21.38M
Price-earnings ratio
0.12
Dividend yield
—
Average volume
24.94K
Volume
13.55K
Open price
$5.31
High today
$5.45
Low today
$5.26
52 Week high
$11.65
52 Week low
$4.85

Kyntra Bio (KYNB) at a glance

As of Oct 20, 2026, Kyntra Bio (KYNB) shares are priced at $5.28, giving the company a market cap of 21.38M and a price-to-earnings ratio of 0.12.

Today the stock has traded between $5.26 and $5.45. The current price is 0.4% above the day's low and 3.1% below its high.

Volume so far is 13.55K shares, below the average of 24.94K shares a day.

Over the past year Kyntra Bio has ranged from $4.85 to $11.65, and now sits 6% of the way up that range.

Kyntra Bio met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$4.69 per share against an estimate of -$3.25.

The average analyst price target is $40.46, 666.3% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $40.46
Low
$35.35
Now
$5.28
High
$45.15

KYNB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 77.6% on average.

  1. Q3 FY24: reported -$4.25 per share against an estimate of -$7.78
  2. Q4 FY24: reported $4.50 per share against an estimate of -$3.57
  3. Q1 FY25: reported $1.25 per share against an estimate of $0.51
  4. Q2 FY25: reported -$1.88 per share against an estimate of -$2.35
  5. Q3 FY25: reported -$3.25 per share against an estimate of -$4.09
  6. Q4 FY25: reported -$3.61 per share against an estimate of -$3.96
  7. Q1 FY26: reported -$3.76 per share against an estimate of -$3.42
  8. Q2 FY26: reported -$4.69 per share against an estimate of -$3.25

Similar companies

Companies in the same industry as Kyntra Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.